The pecking order of the obesity drug market is shifting. Eli Lilly , the $815 billion maker of blockbuster weight-loss drugs ...

Find out about kids' average weight and height from birth to 8 years old – and learn what your child's growth percentile ...

Weight loss medications like Wegovy and Zepbound are gaining popularity as millions turn to them for quick results and potential health benefits.

A recent medical trial could help deliver the first daily weight loss pill capable of cutting down obesity as effectively as ...

Novo Nordisk, maker of Ozempic, applied for FDA approval for a weight loss pill, less than a week after rival Eli Lilly's clinical trial success.

With the growing popularity of weight loss medications, many people are turning to prescription options to help them achieve their health goals. Medications like Ozempic, Mounjaro, and Wegovy are ...

Eli Lilly gains ground with Orforglipron’s success, showing growth potential and risks from momentum and tariffs. Read why ...

Novo Nordisk's stocks face YTD struggles due to trial results and tariffs, but strong fundamentals and outlook justify a Buy.

But this one, for Lilly’s first diabetes and weight-loss pill based on the GLP-1 hormone, was particularly fraught. Days ...

The results bring Eli Lilly's pill orforglipron one step closer to becoming a new, needle-free alternative in the booming weight loss and diabetes market.

(NASDAQ:MTVA) announced positive results from the Phase 1 Part 2 multiple ascending dose (MAD) trial of DA-1726 in obesity.

The Advertising Standards Authority (ASA) discovered about 1,800 unique paid-for weight-loss ads during a search in January that appeared to be promoting prescription-only medications (POMs ...